Skip to main content

Advertisement

SpringerLink
Log in

Safety of parathyroid hormone for the treatment of osteoporosis

  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Teriparatide (recombinant human 1-34 parathyroid hormone) has been registered for the treatment of postmenopausal osteoporosis and osteoporosis in men for more than 5 years, whereas 1-84 parathyroid hormone has just recently been registered in Europe for osteoporosis management. Therefore, more data are available regarding the long-term safety of teriparatide. The issues to be considered are the effects of the registered dose of teriparatide (20 µg/day) on the incidence of hypercalcemia, hypercalciuria, and hyperuricemia, and the US Food and Drug Administration’s “black-box” warning regarding osteogenic sarcoma in the rat model. This review discusses these issues and provides the author’s extensive clinical experience and advice on the use of teriparatide in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434–1441.

    Article  PubMed  CAS  Google Scholar 

  2. Orwoll ES, Scheele WH, Paul S, et al.: The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9–17.

    Article  PubMed  CAS  Google Scholar 

  3. Saag KG, Shane E, Boonen S, et al.: Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357:2028–2039.

    Article  PubMed  CAS  Google Scholar 

  4. Greenspan SL, Bone HG, Macciott TB, et al.: Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH (1-84): results from the TOP study. J Bone Miner Res 2005, 20(Suppl 1):S56.

    Google Scholar 

  5. Miller PD, Bilezikian JP, Deal C, Harris ST: Clinical use of teriparatide in the real world: initial insights. Endocr Pract 2004, 10:139–148.

    PubMed  Google Scholar 

  6. Hodsman AB, Bauer DC, Dempster DW, et al.: Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005, 26:688–703.

    Article  PubMed  CAS  Google Scholar 

  7. Tashjian AH, Gagel RF: Teriparatide (human parathyroid hormone 1-34): two and a half years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 2006, 21:354–365.

    Article  PubMed  CAS  Google Scholar 

  8. Miller PD, Silverman S, Gold DT, et al.: Rationale, objectives, and design of the Direct Analysis of Nonvertebral fracture in the Community Experience (DANCE) study. Osteoporos Int 2006, 17:85–90.

    Article  PubMed  Google Scholar 

  9. Wagman R, Miller PD: The use of teriparatide and PTH (1-84) for the treatment of osteoporosis. Clin Rev Bone Mineral Metab 2006, 4:1–13.

    Article  Google Scholar 

  10. Miller PD, Shergy WJ, Body JJ, et al.: Long-term reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol 2005, 32:1556–1562.

    PubMed  CAS  Google Scholar 

  11. Genant HK, Halse J, Briney WG, et al.: The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin 2005, 21:1027–1034.

    Article  PubMed  CAS  Google Scholar 

  12. Nevitt MC, Chen P, Dore RK, et al.: Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 2006, 17:273–280.

    Article  PubMed  Google Scholar 

  13. Canalis E, Giustina A, Bilezikian JP: Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007, 357:905–916.

    Article  PubMed  CAS  Google Scholar 

  14. McClung M, San Martin J, Miller PD, et al.: Teriparatide and alendronate increase bone mass by opposite effects on bone remodeling. Arch Intern Med 2005, 165:1762–1768.

    Article  PubMed  CAS  Google Scholar 

  15. Chen P, Miller PD, Delmas PD, et al.: Change in lumbar spine bone mineral density and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006, 21:1785–1790.

    Article  PubMed  CAS  Google Scholar 

  16. Chen P, Satterwhite JH, Licata AA, et al.: Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal osteoporosis. J Bone Miner Res 2005, 20:962–970.

    Article  PubMed  CAS  Google Scholar 

  17. Chen P, Miller PD, Recker RR, et al.: Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 2007, 22:1173–1180.

    Article  PubMed  CAS  Google Scholar 

  18. Dempster DW, Cosman F, Kurland AS, et al.: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846–1853.

    Article  PubMed  CAS  Google Scholar 

  19. Jiang Y, Zhao J, Mitlak BH, et al.: Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18:1932–1941.

    Article  PubMed  CAS  Google Scholar 

  20. Zanchetta JR, Bogado CE, Ferretti JL, et al.: Effects of teriparatide [recombinant human parathyroid hormone (1–34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:539–543.

    Article  PubMed  CAS  Google Scholar 

  21. Dobnig H, Sipos AA, Jiang Y, et al.: Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005, 90:3970–3977.

    Article  PubMed  CAS  Google Scholar 

  22. Parfitt AM: Parathyroid hormone and periosteal bone expansion. J Bone Miner Res 2002, 17:1741–1743.

    Article  PubMed  CAS  Google Scholar 

  23. Bringhurst FR: Physiologic actions of PTH and PTHRP: II. Renal actions. In The Parathyroids: Basic and Clinical Concepts. Edited by Bilizikian JP, Marcus R, Levine MA. New York: Academic Press; 2001:227–244.

    Google Scholar 

  24. Strewler GJ: Physiologic actions of PTH and PTHrP: I. Skeletal actions. In The Parathyroids: Basic and Clinical Concepts. Edited by Bilizikian JP, Marcus R, Levine MA. New York: Academic Press; 2001:213–226.

    Google Scholar 

  25. Bilezikian JP, Silverberg SJ: Primary hyperparathyroidism. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, edn 5. Edited by Favus MJ. Washington, DC: American Society for Bone and Mineral Research; 2006:230–235.

    Google Scholar 

  26. Hruska KA, Teitelbaum SL: Renal osteodystrophy. N Engl J Med 1995, 333:166–172.

    Article  PubMed  CAS  Google Scholar 

  27. Slatopolsky E, Brown A, Dusso A: Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999, 73:S14–S19.

    Article  PubMed  CAS  Google Scholar 

  28. Holick M: Vitamin D deficiency. N Engl J Med 2007, 357:266–281.

    Article  PubMed  CAS  Google Scholar 

  29. Heaney RP: The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 2005, 97:13–19.

    Article  PubMed  CAS  Google Scholar 

  30. Coe FL, Favus MJ, Crockett T, et al.: Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1,25(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects. Am J Med 1982, 72:25–32.

    Article  PubMed  CAS  Google Scholar 

  31. Heaney RP, Recker RR, Ryan RA: Urinary calcium in perimenopausal women: normative values. Osteoporos Int 1999, 9:13–18.

    Article  PubMed  CAS  Google Scholar 

  32. Bushinsky DA: Nephrolithiasis. J Am Soc Nephrol 1998, 9:917–924.

    PubMed  CAS  Google Scholar 

  33. Miller PD, Bilezikian JP, Diaz-Curiel M, et al.: Occurrence of hypercalciuria in patients treated with teriparatide. J Clin Endocrinol Metab 2007, 92:3535–3541.

    Article  PubMed  CAS  Google Scholar 

  34. Vahle JL, Sato M, Long GG, et al.: Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 2002, 30:312–321.

    Article  PubMed  CAS  Google Scholar 

  35. Vahle JL, Long GG, Ma YL, Sato M: Bone neoplasms in F344 rats given teriparatide [rhPTH (1–34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004, 32:426–438.

    Article  PubMed  CAS  Google Scholar 

  36. Wilker CE, Jolette J, Smith SY, et al.: No observable carcinogenic effect dose level identified in Fischer 344 rats following daily treatment with PTH (1-84) for 2 years: role of the c-terminal PTH receptor? J Bone Miner Res 2004, 19(Suppl 1):S98.

    Google Scholar 

  37. Harper K, Krege JH, Marcus R, Mitlak BH: Osteosarcoma and teriparatide? J Bone Miner Res 2007, 22:334.

    Article  PubMed  Google Scholar 

  38. Damron TA, Ward WG, Stewart A: Osteosarcoma, chondrosarcoma, and Ewing’s sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res 2007, 459:40–47.

    Article  PubMed  Google Scholar 

  39. Kalra S, Grimer RJ, Spooner D, et al.: Radiation-induced sarcoma of bone: factors that determine outcome. J Bone Joint Surg Br 2007, 89:808–813.

    Article  PubMed  CAS  Google Scholar 

  40. Taghian A, de Vathaire F, Terrier P, et al.: Long-term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Phys 1991, 21:361–367.

    PubMed  CAS  Google Scholar 

  41. Kirova YM, Vilcoq JR, Asselain B, et al.: Radiationinduced sarcomas after radiotherapy for breast carcinoma: a large-scale, single institution review. Cancer 2005, 104:856–863.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Colorado Center for Bone Research, 3190 South Wadsworth Boulevard, Suite #250, Lakewood, CO, 80227, USA

    Paul D. Miller

Authors
  1. Paul D. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul D. Miller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miller, P.D. Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep 6, 12–16 (2008). https://doi.org/10.1007/s11914-008-0003-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-008-0003-y

Keywords

Search

Navigation